Treatment of multiple sclerosis — success from bench to bedside

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis

(2018) X. Montalban et al.   EUROPEAN JOURNAL OF NEUROLOGY

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

(2018) Raju Kapoor et al.   LANCET NEUROLOGY

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

(2018) Xavier Montalban et al.   Multiple Sclerosis Journal

Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis

(2018) Mathias Granqvist et al.   JAMA Neurology

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

(2018) Xavier Montalban et al.   Multiple Sclerosis Journal

An Autopsy Case of Fulminant Hepatitis in a Patient with Multiple Sclerosis Treated by Interferon-Beta-1a

(2017) Yuichi Yamazaki et al.   INTERNAL MEDICINE

Efficiency of antibody therapy in demyelinating diseases

(2017) Tetsuya Akaishi et al.   INTERNATIONAL IMMUNOLOGY

Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases

(2017) Robbert-Jan Gieselbach et al.   JOURNAL OF NEUROLOGY

Evolving concepts in the treatment of relapsing multiple sclerosis

(2017) Giancarlo Comi et al.   LANCET

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

(2017) Pei-Ran Ho et al.   LANCET NEUROLOGY

Oral Presentations

(2017)   Multiple Sclerosis Journal

Late Breaking News Abstracts

(2017)   Multiple Sclerosis Journal

Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets

(2017) Nicola De Stefano et al.   Multiple Sclerosis Journal

Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

(2017) Gavin Giovannoni et al.   Multiple Sclerosis Journal

Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod

(2017) Mahtab Ghadiri et al.   Multiple Sclerosis Journal

Treatment decisions in multiple sclerosis — insights from real-world observational studies

(2017) Maria Trojano et al.   Nature Reviews Neurology

Alemtuzumab CARE-MS I 5-year follow-up

(2017) Eva Havrdova et al.   NEUROLOGY

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2017) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date

(2017) Alberto Gajofatto   Drug Design Development and Therapy

Progressive Multifocal Leukoencephalopathy and Monoclonal Antibodies

(2017) Chandrashekar Bohra et al.   Cancer Control

Oral Presentations

(2017)   Multiple Sclerosis Journal

Late Breaking News Abstracts

(2017)   Multiple Sclerosis Journal

Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets

(2017) Nicola De Stefano et al.   Multiple Sclerosis Journal

Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study

(2017) Gavin Giovannoni et al.   Multiple Sclerosis Journal

Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod

(2017) Mahtab Ghadiri et al.   Multiple Sclerosis Journal

Classifying PML risk with disease modifying therapies

(2017) Joseph R. Berger   Multiple Sclerosis and Related Disorders

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks

(2017) Barry A. Singer   Therapeutic Advances in Neurological Disorders

Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis

(2016) Robert J. Fox et al.   Contemporary Clinical Trials

Interferon-induced pulmonary hypertension

(2016) Laurent Savale et al.   CURRENT OPINION IN PULMONARY MEDICINE

Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis

(2016) María Rosario Blasco et al.   JOURNAL OF NEUROLOGY

Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study

(2016) Caryl J. Schwartzbach et al.   JOURNAL OF NEUROLOGY

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

(2016) Fred Lublin et al.   LANCET

Personalised medicine for multiple sclerosis care

(2016) Arie Gafson et al.   Multiple Sclerosis Journal

Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy–NO

(2016) Robert T Naismith   Multiple Sclerosis Journal

Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy–Commentary

(2016) Aaron E Miller   Multiple Sclerosis Journal

Shared decision-making in multiple sclerosis

(2016) Erica Colligan et al.   Multiple Sclerosis Journal

Dimethyl fumarate is coming of age

(2016) Mar Tintoré et al.   Nature Reviews Neurology

Rituximab for treating multiple sclerosis

(2016) Dennis Bourdette   NEUROLOGY

Personalised medicine for multiple sclerosis care

(2016) Arie Gafson et al.   Multiple Sclerosis Journal

Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy–NO

(2016) Robert T Naismith   Multiple Sclerosis Journal

Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy–Commentary

(2016) Aaron E Miller   Multiple Sclerosis Journal

Shared decision-making in multiple sclerosis

(2016) Erica Colligan et al.   Multiple Sclerosis Journal

Dimethyl fumarate in relapsing–remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety

(2015) Duvyanshu Dubey et al.   Expert Review of Neurotherapeutics

Multiple sclerosis—a quiet revolution

(2015) Richard M. Ransohoff et al.   Nature Reviews Neurology

Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis

(2015) Jens Ingwersen et al.   Neurotherapeutics

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

(2015) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dimethyl fumarate in relapsing–remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety

(2015) Duvyanshu Dubey et al.   Expert Review of Neurotherapeutics

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

(2014) Jeremy Chataway et al.   LANCET

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

(2014) Gavin Giovannoni et al.   LANCET NEUROLOGY

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

(2014) Aaron E Miller et al.   LANCET NEUROLOGY

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial

(2014) Thomas P Leist et al.   LANCET NEUROLOGY

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

(2014) Christian Confavreux et al.   LANCET NEUROLOGY

Significant clinical worsening after natalizumab withdrawal: Predictive factors

(2014) A Vidal-Jordana et al.   Multiple Sclerosis Journal

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis

(2014) Hans-Peter Hartung et al.   Multiple Sclerosis Journal

Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis

(2014) G. Karlsson et al.   NEUROLOGY

Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial

(2014) J. Romme Christensen et al.   NEUROLOGY

Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis

(2013) Omar Khan et al.   ANNALS OF NEUROLOGY

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

(2013) Ralf Gold et al.   LANCET

Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial

(2013) John Zajicek et al.   LANCET NEUROLOGY

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

(2013) Patrick Vermersch et al.   Multiple Sclerosis Journal

Interferon   for secondary progressive multiple sclerosis: a systematic review

(2012) L. L. Mantia et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study

(2011) S Cook et al.   Multiple Sclerosis Journal

A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS

(2011) M. S. Freedman et al.   NEUROLOGY

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

(2011) P. W. O'Connor et al.   NEUROLOGY

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

(2011) Paul O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial

(2010) Raju Kapoor et al.   LANCET NEUROLOGY

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE